Statistical Considerations in the Development and Evaluation of Therapeutic Biomarkers in Cancer - Therapeutic Biomarkers in Cancer - page 57

setting of neoadjuvant chemotherapy, Clin. Pharmacol. Ther. , 86 , 97-

100.
38. Berry, D. A. (2011). Adaptive clinical trials: The promise and the
caution, , 606-609.

39. Korn, E. L. Freidlin, B. (2011). Outcome-adaptive randomization: is it
useful?

J. Clin. Oncol ., 29

, 771-776.
40. Yuan, Y. Yin, G. (2011). On the usefulness of outcome-adaptive
randomization.

J. Clin. Oncol., 29

, e390-e392.
41. Korn E. L. Freidlin, B. (2011). Reply to Y. Yuan

J. Clin. Oncol ., 29

et al. : on the usefulness

, e393.
42. Freidlin, B., McShane, L. M., Korn, E. L. (2010). Randomized clinical
trials with biomarkers: design issues,

of outcome-adaptive randomization, J. Clin. Oncol ., 29

J. Natl. Cancer Inst ., 102 , 152-

160.
43. S1201 Trial: Combination Chemotherapy in Treating Patients With

Advanced or Metastatic Esophageal Cancer, Gastric Cancer, or

, http://clinicaltrials.gov/ct2/show/
NCT01498289 (last accessed 3/19/12).
44. S0819 Trial: Carboplatin and Paclitaxel With or Without Bevacizumab
and/or Cetuximab in Treating Patients With Stage IV or Recurrent
Non-Small Cell Lung Cancer, http://www.clinicaltrials.gov/ct2/show/
NCT00946712 (last accessed 3/19/12).
45. CALGB-10603Trial:

Gastroesophageal Junction Cancer

Daunorubicin, Cytarabine, and Midostaurin in
Treating Patients With Newly Diagnosed Acute Myeloid Leukemia ,

http://www.clinicaltrials.gov/ct2/show/NCT00651261 (la st accessed
3/19/12).
46. Stone, R. M., Dohner, H., Ehninger, G., Villeneuve, M., Teasdale, T.,
Virkus, J. D., Bressler, L. R., Seiler, M. M., Marcucci, G., Larson, R. A. on
behalf of all study investigators. (2011). CALGB 10603 (RATIFY): A
randomized phase III study of induction (daunorubicin/cytarabine)
and consolidation (high-dose cytarabine) chemotherapy combined
with midostaurin or placebo in treatment-naive patients with FLT3
mutated AML. [Abstract], (Suppl 15): A-TPS199.

47. Cobo, M., Isla, D., Massuti, B., Montes, A., Sanchez, J. M., Provencio,
M., Vinolas, N., Paz-Ares, L., Lopez-Vivanco, G., Munoz, M. A., Felip, E.,
Alberola, V., Camps, C., Domine, M., Sanchez, J. J., Sanchez-Ronco, M.,
Danenberg, K., Taron, M., Gandara, D., Rosell, R. (2007). Customizing
cisplatin based on quantitative excision repair cross-complementing 1
mRNA expression: a phase III trial in non-small-cell lung cancer,

J. Clin. Oncol ., 29

J. Clin.

Oncol ., 25 , 2747-2754.